$TECH — AVOID 📊

$TECH — AVOID 📊 Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and biopro 🎯 Q1 FY26 | Rev $0B | EPS $0.53 vs $0.53 ➖ 💡 Consensus expected in-line results, and the company delivered exactly that. There is no variant view suggesting mispricing; the stock appears overvalued relative to historical norms and factor model rankings (0th percentile sector/universe). 📉 Reward/Risk: 0.51:1 🏢 Business Quality: 5/10 - Speculative growth stage, limited visibility on profitability; $100B market cap on $1.2B annual revenue implies unproven unit economics. 📊 Valuation: rich — P/E 82.8x vs historical range 75.6-82.0x, median 78.8x (112th percentile); P/S ~80x; factor ranks at rock bottom; no clear support from... 📊 Our read: AVOID. Full analysis → https://stockduty.xyz/s/TECH0621 Also in play: $AAPL $GOOGL $MSFT $AMZN $META $TSM

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and biopro